Eli Lilly (LLY) Announced Results for its Once-Weekly Insulin

Eli Lilly and Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On June 22, Eli Lilly and Company (NYSE:LLY) announced new results for its once-weekly insulin, Efsitora alfa. The drug is being tested for adults with type 2 diabetes.

The company released results for QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials. Each trial looked at a different group of patients. QWINT-1 looked at people starting insulin for the first time, QWINT-3 looked at people already using insulin daily, and QWINT-4 tested people who used both daily basal and mealtime insulin. The main goal was to see if Efsitora could lower A1C as well as daily insulin.

Results showed that Eli Lilly and Company (NYSE:LLY)’s Efsitora lowered A1C by 1.31% for QWINT-1, 0.58% for QWINT-3, and 1.07% after 26 weeks for QWINT-4. The treatment is notable as Efsitora only needs to be injected once a week.

Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company that focuses on diabetes, oncology, immunology, neuroscience, and other therapeutic areas.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.